CAS No.: | 1702967-37-0 |
---|---|
Formula: | C49h71n9o16 |
EINECS: | N/a |
Type: | Pharmaceutical Intermediates |
Appearance: | Powder |
Quality: | Crude |
Samples: |
---|
Customization: |
---|
Suppliers with verified business licenses
Product name | PSMA-617 |
CAS No. | 1702967-37-0 |
MF | C49H71N9O16 |
MW | 1042.14 |
Melting point | N/A |
Boiling point | 1371.9±65.0 °C(Predicted) |
Density | 1.322±0.06 g/cm3(Predicted) |
Storage | N/A |
Prostate-specific membrane antigen (PSMA)-targeting radio-ligand therapy with beta-emitting Lutetium has already been investigated in several early phase dosimetry studies, demonstrated promising results in phase-2, and recently the first phase-3 trial finished recruitment. In contrast, PSMA-targeting alpha-particle therapy (TAT) has only been evaluated in few preclinical experiments, preliminary dosimetry attempts and some retrospective observational studies, yet.
Our Product purity and quality is guaranteed by lab test for each batch
Suppliers with verified business licenses